hdr isap

Organisation

Organization

The International Society of Anti-Infective Pharmacology is an interdisciplinary scientific society for the study of pharmacodynamics and pharmacokinetics and for the improvement of dosing of anti-infectives.

Please make a selection in the submenu on the left to see more about our organization.

Read more

Officers and Directing Bodies

  • President

    (2017-2018)

    Roger Nation, PhD
    Monash University, Parkville, Australia
    This email address is being protected from spambots. You need JavaScript enabled to view it.
  • Secretariat

    (2017-2018)

    Lena Friberg, PhD
    Uppsala University, Uppsala, Sweden
    This email address is being protected from spambots. You need JavaScript enabled to view it.

    Sebastian Wicha, PhD
    University of Hamburg, Hamburg, Germany
    This email address is being protected from spambots. You need JavaScript enabled to view it.
  • Treasurer

    (2014-2018)

    Brian Tsuji, PharmD
    State University of New York at Buffalo, Buffalo, NY, USA
    This email address is being protected from spambots. You need JavaScript enabled to view it.
  • President-elect

    (2017-2018)

    Brian Tsuji, PharmD
    State University of New York at Buffalo, Buffalo, NY, USA
    This email address is being protected from spambots. You need JavaScript enabled to view it.
  • Council

    (2017-2018)

    • Hartmut Derendorf, PhD; University of Florida, Gainesville, FL, USA This email address is being protected from spambots. You need JavaScript enabled to view it.
    • Johan W. Mouton, MD; Erasmus Medical Centre, Rotterdam, The Netherlands This email address is being protected from spambots. You need JavaScript enabled to view it.
    • Justin Lenhard, PharmD; California Northstate University, Elk Grove, USA This email address is being protected from spambots. You need JavaScript enabled to view it.
    • Markus Zeitlinger, MD; Medical University of Vienna, Vienna, Austria This email address is being protected from spambots. You need JavaScript enabled to view it.
    • Vincent H. Tam, PharmD; University of Houston College of Pharmacy, Houston, TX, USA This email address is being protected from spambots. You need JavaScript enabled to view it.
    • Ursula Theuretzbacher, PhD; Center for Anti-Infective Agents, Vienna, Austria This email address is being protected from spambots. You need JavaScript enabled to view it.
  • Past-presidents

    (1991-2016)

    • William A. Craig, MD, Madison, WI (Founding president; president -1991-1994)
    • Otto Cars, MD, Uppsala, Sweden (1994-1996)
    • Mike N. Dudley, PharmD, San Diego, CA (1996-1998)
    • Paul M. Tulkens, MD, PhD, Brussels, Belgium (1998-2000)
    • George L. Drusano, MD, Gainesville, Fl (2000-2002)
    • Johan W. Mouton, MD, Nijmegen, The Netherlands (2002-2004)
    • Hartmut Derendorf, PhD, Gainesville, Fl (2004-2006)
    • Fritz Sörgel, PhD, Nürnberg, Germany (2006-2008)
    • David Andes, MD, Madison, WI (2008-2010)
    • Alasdair P. MacGowan, PhD, Bristol,UK (2010-2012)
    • Paul Ambrose, PharmD, FIDSA, Latham, NY, USA (2012-2014)
    • Ursula Theuretzbacher, PhD, Vienna, Austria (2014-2016)

 

Read more

History

History

The Society was created officially in 1991, but found its roots in informal and formal meetings among attendees of ICAAC and other major Conferences deraling with Chemotherapy around the years 1986-1989. An historical landmark in this venture was a meeting held in Stockholm, Sweden, in June 1989, organized by W.A. Craig (Madison, WI) and Otto Cars (Upssala, Sweden) where several of the future founding members discussed the importance of pharmacodynamics and pharmacokinetics for the apropriate, and possibly improved use of antibiotics.

Read more

Partner organizations

Partner organizations

ISAP is closely collaborating with EPASG - ESCMID (European Society for Clinical Microbiology and Infectious Diseases) PK/PD of Anti-Infectives Study Group

Read more

Polymyxin presentations 2013

Program for the 1st International Conference on Polymyxins
with links to the presentations

Thursday 2 May 2013

8:15 – 9:15

Registration

9:15 – 10:00

Chairs
Roger Nation
Jian Li
SESSION 1: Welcome, program overview and introduction to the polymyxins

· Key features of the polymyxins
Roger Nation (30 min)

10:00 – 10:30

Morning tea, poster viewing and networking

10:30 – 12:30

Chairs

David Paterson

Otto Cars

SESSION 2: The use of polymyxins in clinical practice

· Establishing the clinical need for polymyxins
David Paterson (25 min)

· Clinical outcomes in polymyxin studies: what are the challenges?
Fernanda Silveira (15 min)

· Are polymyxins effective? A meta-analysis of polymyxin use
Mical Paul (20 min)

· Snapshots of polymyxin use around the world:
12:30 – 13:45

Lunch, poster viewing and networking

13:45 – 15:45

Chairs

John Turnidge

Dennis Dixon

SESSION 3: Towards optimized dosing of intravenous colistin and polymyxin B

·  Critical preclinical PK/PD information
Vincent Tam (15 min)

·  Intravenous polymyxins in critically-ill patients: how can we fit the dose to the patient?

    - Importance of the loading dose: CMS vs polymyxin B     

Lena Friberg (15 min)

     - Selection of individualized maintenance doses for various categories of patients: CMS vs polymyxin B    

Roger Nation (30 min)

· Dosing in other special patient populations
Helen Giamarellou (20 min)

· Risk factors for nephrotoxicity
Alan Forrest (10 min)

·  Managing patients with declining kidney function and other adverse effects
Visanu Thamlikitkul (20 min)

15:45 – 16:15

Afternoon tea, poster viewing and networking

16:15 – 18:00

Chairs

Keith Kaye

Ursula Theuretzbacher

SESSION 4: What is the role of inhaled polymyxins for treatment of respiratory tract infections?

· Inhaled polymyxins: what can we learn from pulmonary delivery of other antibiotics?
Mike Dudley (20 min)

· Pulmonary disposition of polymyxins
William Couet (20 min)

·  Inhalational +/- intravenous administration of polymyxins for treatment of VAP
Helen Giamarellou (25 min)

· Use of polymyxins in patients with cystic fibrosis
Niels Høiby (25 min)

18:00 – 19:30

Reception on the Terrace

Friday 3 May 2013

9:00 – 11:00

Chairs

Brian Tsuji

Fernanda Silveira

SESSION 5: Polymyxins: mono-therapy or a combination?

· Preclinical approaches: What is important – synergy or activity of combinations?
Brian Tsuji (20 min)

· Translational approaches to inform selection of rational combinations for patients
Juergen Bulitta (20 min)

· Clinical trials of monotherapy versus combinations
o   Colistin/fosfomycin      Visanu Thamlikitkul (20 min)
o   Colistin/rifampicin        Claudio Viscoli (20 min)
o   Colistin/carbapenems  Keith Kaye and Johan Mouton (10 min each)

11:00 – 11:30

Morning tea, poster viewing and networking

11:30 – 12:30

Chairs

John Turnidge

Johan Mouton

SESSION 6: Susceptibility and breakpoints

· In vitro susceptibility testing: what are the critical issues?
John Turnidge (25 min)

· Polymyxin breakpoints: what needs attention?
Johan Mouton (25 min)

12:30 – 13:45

Lunch, poster viewing and networking

13:45 – 15:00

 

 

Chairs

Robert Bonomo

Irene Plank

SESSION 7: Mechanisms of activity, resistance and nephrotoxicity: how understanding may be used advantageously

· Mechanisms of antibacterial activity
Brian Tsuji (20 min)

· Mechanisms of resistance
Robert Bonomo (20 min)

· Bacterial biofilm and resistance
Niels Høiby (15 min)

· Mechanisms of nephrotoxicity
Jian Li (15 min)

15:00 – 15:30

Afternoon tea, poster viewing and networking

15:30 – 16:30

 

 

Chairs

Otto Cars

Vincent Tam

 

SESSION 8: Oral presentations of selected abstracts

· Abstract O-1
Murat Dizbay (8 min)

· Abstract O-2
Claudio Viscoli (8 min)

· Abstract O-3
Luisa Sorlí (8 min)

· Abstract O-4
Jason Pogue (8 min)
16:30 – 17:30

 
 

 


Chair

David Paterson

SESSION 9: Colistin and polymyxin B: are they peas in a pod or chalk and cheese?

A lively, entertaining and most importantly informative debate between two teams in which colistin and polymyxin B will be compared and contrasted. Might one have advantages over the other in regard to various considerations? The audience will have an opportunity to vote.

The topics are:

· The ability to achieve ‘appropriate’ plasma concentrations
Vincent Tam (Poly B team) vs John Turnidge (CMS team)

· Targeting specific infections (UTI, respiratory, CNS)
Matti Karvanen (Poly B team) vs William Couet (CMS team)

· Clinical effectiveness and adverse effects
Alexandre Zavascki (Poly B team) vs Keith Kaye (CMS team)

18:30 –

Conference dinner

Saturday 4 May 2013

9:00 – 10:00

 


Chairs

Ursula Theuretzbacher William Couet

SESSION 10: Oral presentations of selected abstracts

· Abstract O-5
William Couet (8 min)

· Abstract O-6
Olivia Bargiacchi (8 min)

· Abstract O-7
Teysir Halaby (8 min)

· Abstract O-8
Gunther Kern (8 min)

10:00 – 10:30

Chairs

Dennis Dixon
Irene Plank


SESSION 11: EU and NIH programs facilitating antibacterial resistance research

·  Outlines of the key programs of the NIH and EU will be provided
Irene Plank and Dennis Dixon

10:30 – 11:00

Morning tea and networking

11:00 – 12:30

 
 

Chairs

Roger Nation
Jian Li


SESSION 12: The Prato Polymyxin Consensus

· Key topics and issues identified during the preceding symposia will be brought to this session and discussed by a panel, with ample opportunity for input from the audience

· Recommendations will be made on aspects impacting the future clinical use of polymyxins and high-priority areas for research, and the audience will be asked to vote on whether they do or don’t support the recommendations

· The outcome will be the basis of the Prato Polymyxin Consensus which will summarize high-priority areas requiring attention

Panel members:

David Paterson
Johan Mouton
Keith Kaye
Ursula Theuretzbacher
Brian Tsuji
Mike Dudley
John Turnidge

· The 2nd International Polymyxin Conference: when and where?

· Conference close

12:30 – 13:30

Lunch and departure to airport or other

Activities

Please select from the menu
  • President

    (2017-2018)

    Roger Nation, PhD
    Monash University, Parkville, Australia
    This email address is being protected from spambots. You need JavaScript enabled to view it.
  • Secretariat

    (2017-2018)

    Lena Friberg, PhD
    Uppsala University, Uppsala, Sweden
    This email address is being protected from spambots. You need JavaScript enabled to view it.

    Sebastian Wicha, PhD
    University of Hamburg, Hamburg, Germany
    This email address is being protected from spambots. You need JavaScript enabled to view it.
  • Treasurer

    (2014-2018)

    Brian Tsuji, PharmD
    State University of New York at Buffalo, Buffalo, NY, USA
    This email address is being protected from spambots. You need JavaScript enabled to view it.
  • President-elect

    (2017-2018)

    Brian Tsuji, PharmD
    State University of New York at Buffalo, Buffalo, NY, USA
    This email address is being protected from spambots. You need JavaScript enabled to view it.
  • Council

    (2017-2018)

    • Hartmut Derendorf, PhD; University of Florida, Gainesville, FL, USA This email address is being protected from spambots. You need JavaScript enabled to view it.
    • Johan W. Mouton, MD; Erasmus Medical Centre, Rotterdam, The Netherlands This email address is being protected from spambots. You need JavaScript enabled to view it.
    • Justin Lenhard, PharmD; California Northstate University, Elk Grove, USA This email address is being protected from spambots. You need JavaScript enabled to view it.
    • Markus Zeitlinger, MD; Medical University of Vienna, Vienna, Austria This email address is being protected from spambots. You need JavaScript enabled to view it.
    • Vincent H. Tam, PharmD; University of Houston College of Pharmacy, Houston, TX, USA This email address is being protected from spambots. You need JavaScript enabled to view it.
    • Ursula Theuretzbacher, PhD; Center for Anti-Infective Agents, Vienna, Austria This email address is being protected from spambots. You need JavaScript enabled to view it.
  • Past-presidents

    (1991-2016)

    • William A. Craig, MD, Madison, WI (Founding president; president -1991-1994)
    • Otto Cars, MD, Uppsala, Sweden (1994-1996)
    • Mike N. Dudley, PharmD, San Diego, CA (1996-1998)
    • Paul M. Tulkens, MD, PhD, Brussels, Belgium (1998-2000)
    • George L. Drusano, MD, Gainesville, Fl (2000-2002)
    • Johan W. Mouton, MD, Nijmegen, The Netherlands (2002-2004)
    • Hartmut Derendorf, PhD, Gainesville, Fl (2004-2006)
    • Fritz Sörgel, PhD, Nürnberg, Germany (2006-2008)
    • David Andes, MD, Madison, WI (2008-2010)
    • Alasdair P. MacGowan, PhD, Bristol,UK (2010-2012)
    • Paul Ambrose, PharmD, FIDSA, Latham, NY, USA (2012-2014)
    • Ursula Theuretzbacher, PhD, Vienna, Austria (2014-2016)

Disclaimer

This website is financed, owned and operated by the Society of Anti-Infective Pharmacology, a registered non-profit organization in the US.

Copyright: ISAP maintains the copyright for all material on the ISAP website with all rights reserved. Any copyright violation may result in ISAP protecting its rights.

Disclaimer:

ISAP cannot provide any guarantees and cannot be held liable for any errors, inaccuracies or incompleteness of any information given on this website by officers or employees of ISAP or any other third party the views and opinions expressed by individual authors of articles, presentations or discussion/opinion papers etc. do not necessarily reflect those of ISAP.

ISAP links to many websites created and maintained by other public and/or private organizations as a service to the users. The presence of a link is not an ISAP endorsement of the site. ISAP is not responsible for the information collection practices of non-ISAP sites.

ISAP is not liable in any way and without any limit towards any party for any kind of damage, loss or harm that might be caused by visiting this website. It is not ISAP’s responsibility to make sure that your system is free of viruses and any other kind of possibly harmful issues. ISAP does not guarantee that any other site you obtain access to through this website is free of any such potentially harmful items.

  • 1
  • 2